NanoViricides says MPox drug candidate NV-387 poised for Phase II...
NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization’s recent extension of the Public Health Emergency of International Concern (PHEIC) for the Mpox virus outbreak. The extension, …